This finding provides further evidence supporting the cardiovascular benefits of exercise
Spiering, B., Kraemer, W., Hatfield, D., Vingren, J., Fragala, M., Ho, J., Thomas, G., Hkkinen, K
In a study funded by Novo Nordisk, after discontinuing treatment with semaglutide, gains in cardiometabolic health (such as improved blood pressure, cholesterol levels, and blood sugar) reverted back toward initial levels, and participants regained two-thirds of the weight they had lost, suggesting the drugs may need to be taken long-term, possibly for the life of the patient
Procedemos de todas partes del mundo